iNtRON Biotechnology and Estech Pharma today announced that they have entered into the collaboration agreement on eHeme (engineered Heme) technology development. According to iNtRON Bio, two companies will make an investment together in the bio and chemical production of eHeme based on the iNtRON Bio’s relevant patents....
iNtRON Biotechnology held the corporate presentation for private and institutional investors on February 19, 2019. The purpose of the corporate presentation was to increase shareholders’ understanding about the company and investment value. During the corporate presentation, Seong Jun Yoon, CEO & Founder, made a presentation regarding...
Roivant plans to initiate Phase 2 clinical trial in 2019 Agreement includes option to in-license additional anti-Gr(+) programs Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of...
iNtRON Biotechnology has announced that N-Rephasin BAL200 for the treatment of anthrax infection has been received Orphan Drug Designation (ODD) from the US Food and Drug Administration (US FDA). Orphan Drug Designation is a program of FDA to support for the new drug development of rare...
On June 22, 2018, The 6th Korea Bacteriophage Research Society meeting was held at the iNtRON Bio’s conference room. 40 prominent bacteriophage researchers and related industry specialists have participated in the meeting, and Professor Yong of Yonsei University, Professor Bae of Seoul National University, and Research...
To Focus on Investor Relations and Global Business Development As iNtRON Biotechnology (hereafter “iNtRON”) has grown up steadily, iNtRON has opened a new Seoul Office in the center of Seoul with great accessibility to focus on global business and investor relations. iNtRON is developing novel...